CD274 and lung cancer: To date, most EV-related clinical trials were designed for lung cancer to detect genetic mutations and programmed cell death ligand 1 (PD-L1) expression in combination with targeted therapy or immunotherapy, and they were primarily based on blood-derived EVs [110].